Toward antivirals against hepatitis E: In the steps of hepatitis C
- PMID: 37300387
- DOI: 10.1097/HEP.0000000000000509
Toward antivirals against hepatitis E: In the steps of hepatitis C
Comment on
-
Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hepatitis E patients.Hepatology. 2023 Dec 1;78(6):1882-1895. doi: 10.1097/HEP.0000000000000514. Epub 2023 Jun 20. Hepatology. 2023. PMID: 37334496 Free PMC article.
References
-
- Kamar N, Izopet J, Pavio N, Aggarwal R, Labrique A, Wedemeyer H, et al. Hepatitis E virus infection. Nat Rev Dis Primers. 2017;3:17086.
-
- Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Niu C, Zennou V, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2012;56:3359–3368.
-
- World Health O. World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization; 2021.
-
- Dao Thi VL, Debing Y, Wu X, Rice CM, Neyts J, Moradpour D, et al. Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin. Gastroenterology. 2016;150:82–85 e84.
-
- Lampejo T. Sofosbuvir in the treatment of hepatitis E virus infection: A review of in vitro and in vivo evidence. J Clin Exp Hepatol. 2022;12:1225–1237.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
